JP2017537067A - ヘパリン結合性上皮成長因子様成長因子を用いた、扁桃摘出後の上皮再生促進の方法 - Google Patents

ヘパリン結合性上皮成長因子様成長因子を用いた、扁桃摘出後の上皮再生促進の方法 Download PDF

Info

Publication number
JP2017537067A
JP2017537067A JP2017521530A JP2017521530A JP2017537067A JP 2017537067 A JP2017537067 A JP 2017537067A JP 2017521530 A JP2017521530 A JP 2017521530A JP 2017521530 A JP2017521530 A JP 2017521530A JP 2017537067 A JP2017537067 A JP 2017537067A
Authority
JP
Japan
Prior art keywords
egf
composition
tonsillectomy
wound
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017521530A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537067A5 (enExample
Inventor
マリア ピーター ルーク サンタ
マリア ピーター ルーク サンタ
クロエ ドムヴィル‐ルイス
クロエ ドムヴィル‐ルイス
ダニエル ベスウィック
ダニエル ベスウィック
ロブソン カパッソ
ロブソン カパッソ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2017537067A publication Critical patent/JP2017537067A/ja
Publication of JP2017537067A5 publication Critical patent/JP2017537067A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2017521530A 2014-10-21 2015-10-21 ヘパリン結合性上皮成長因子様成長因子を用いた、扁桃摘出後の上皮再生促進の方法 Pending JP2017537067A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462066564P 2014-10-21 2014-10-21
US62/066,564 2014-10-21
PCT/US2015/056651 WO2016064998A1 (en) 2014-10-21 2015-10-21 Promoting epithelial regeneration post tonsillectomy using heparin binding epidermal growth factor like growth factor

Publications (2)

Publication Number Publication Date
JP2017537067A true JP2017537067A (ja) 2017-12-14
JP2017537067A5 JP2017537067A5 (enExample) 2018-11-29

Family

ID=55761476

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017521530A Pending JP2017537067A (ja) 2014-10-21 2015-10-21 ヘパリン結合性上皮成長因子様成長因子を用いた、扁桃摘出後の上皮再生促進の方法

Country Status (6)

Country Link
US (2) US20170232065A1 (enExample)
EP (1) EP3209322A4 (enExample)
JP (1) JP2017537067A (enExample)
AU (2) AU2015336008B2 (enExample)
CA (1) CA2964378A1 (enExample)
WO (1) WO2016064998A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210138036A1 (en) * 2014-10-21 2021-05-13 The Board Of Trustees Of The Leland Stanford Junior University Method for Treating or Preventing Radiotherapy-and Chemotherapy-Associated Oral Mucositis Using Locally Administered Heparin Binding Epidermal Growth Factor Like Growth Factor (HB-EGF)
WO2019231860A1 (en) * 2018-05-27 2019-12-05 The Board Of Trustees Of The Leland Stanford Junior University Method for treating or preventing radiotherapy- and chemotherapy-associated oral mucositis using locally administered heparin binding epidermal growth factor like growth factor (hb-egf)
EP3820460A1 (en) * 2018-07-12 2021-05-19 The Board of Trustees of the Leland Stanford Junior University Methods for reversing hiv latency using baf complex modulating compounds
JP7475611B2 (ja) * 2019-05-31 2024-04-30 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 粘膜付着性ミクロゲル組成物およびそれを使用するための方法
US20240050593A1 (en) * 2020-12-18 2024-02-15 Duke University Compositions For and Methods of Enhancing Spinal Cord Tissue Regeneration

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06502538A (ja) * 1990-10-16 1994-03-24 ザ　チルドレンズメディカルセンターコーポレーション 上皮細胞成長因子（ｅｇｆ）との相同性をもつヘパリン結合性マイトジェン
WO2007061411A2 (en) * 2005-11-21 2007-05-31 Kevin Todd Kotecki A method for developing and marketing a post operative home recovery kit for use by a patient after discharge from a hospital and for recuperation at home
JP2009543778A (ja) * 2006-07-10 2009-12-10 シネクサス， インコーポレイテッド 洞口鼻道複合体へ活性薬剤を放出するための移植可能な持続性薬物送達装置
US20130165376A1 (en) * 2007-04-30 2013-06-27 Nationwide Children's Hospital Inc. Heparin Binding Epidermal Growth Factor (HB-EGF) for Use in Methods of Treating and Preventing Intestinal Injury Related to Hemorrhagic Shock and Resuscitation
US20140154236A1 (en) * 2009-04-27 2014-06-05 Intersect Ent, Inc. Devices and methods for treating pain associated with tonsillectomies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112620A (en) * 1990-09-20 1992-05-12 Mikkur, Inc. Polyethylene glycol ointment for apthous ulcers
US6682501B1 (en) * 1996-02-23 2004-01-27 Gyrus Ent, L.L.C. Submucosal tonsillectomy apparatus and method
US8912165B2 (en) * 1999-03-12 2014-12-16 Biotec Pharmacon Asa Methods of skin treatment and use of water-soluble β-(1,3) glucans as active agents for producing therapeutic skin treatment agents
WO2007014167A2 (en) * 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions for and methods of treating epithelial diseases with growth factors
US10058631B2 (en) * 2014-07-09 2018-08-28 Cook Medical Technologies Llc Tonsillectomy sponge
EP3573697A4 (en) * 2017-01-27 2020-11-11 The UAB Research Foundation PROLONGED INTRA-TONSILLARY DRUG ADMINISTRATION WITH NEEDLE NETWORK

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06502538A (ja) * 1990-10-16 1994-03-24 ザ　チルドレンズメディカルセンターコーポレーション 上皮細胞成長因子（ｅｇｆ）との相同性をもつヘパリン結合性マイトジェン
WO2007061411A2 (en) * 2005-11-21 2007-05-31 Kevin Todd Kotecki A method for developing and marketing a post operative home recovery kit for use by a patient after discharge from a hospital and for recuperation at home
JP2009543778A (ja) * 2006-07-10 2009-12-10 シネクサス， インコーポレイテッド 洞口鼻道複合体へ活性薬剤を放出するための移植可能な持続性薬物送達装置
US20130165376A1 (en) * 2007-04-30 2013-06-27 Nationwide Children's Hospital Inc. Heparin Binding Epidermal Growth Factor (HB-EGF) for Use in Methods of Treating and Preventing Intestinal Injury Related to Hemorrhagic Shock and Resuscitation
US20140154236A1 (en) * 2009-04-27 2014-06-05 Intersect Ent, Inc. Devices and methods for treating pain associated with tonsillectomies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIM JM. ET AL., ORAL DISEASES, vol. Vol. 17, Issue 8, JPN6019031096, November 2011 (2011-11-01), pages 785 - 793, ISSN: 0004183565 *
VAIMAN MICHAEL ET AL., MEDICAL SCIENCE MONITOR, vol. 17, no. 10, JPN6019031097, 2011, pages 25 - 31, ISSN: 0004094057 *

Also Published As

Publication number Publication date
AU2015336008A1 (en) 2017-05-25
CA2964378A1 (en) 2016-04-28
AU2019272030A1 (en) 2019-12-19
EP3209322A1 (en) 2017-08-30
US20210038690A1 (en) 2021-02-11
EP3209322A4 (en) 2018-07-18
US20170232065A1 (en) 2017-08-17
AU2015336008B2 (en) 2019-11-21
WO2016064998A1 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
US20210038690A1 (en) Promoting epithelial regeneration using heparin binding epidermal growth factor like growth factor
US20210290539A1 (en) Engineered hemichannels, engineered vesicles, and uses thereof
WO2015187295A2 (en) Methods of lowering serum cholesterol
US11891424B2 (en) Methods and compositions for regenerating tissues
KR20200031143A (ko) 국소 조성물 및 용도
US20250277010A1 (en) Agent for treatment of dermatological disorders
CN111465408B (zh) 一种预防或治疗骨关节炎的方法和药物
EP4091621A1 (en) Method for treatment of nerve injury and related disease
US20210138036A1 (en) Method for Treating or Preventing Radiotherapy-and Chemotherapy-Associated Oral Mucositis Using Locally Administered Heparin Binding Epidermal Growth Factor Like Growth Factor (HB-EGF)
RU2799211C2 (ru) Средство для лечения дерматологических заболеваний
US20110092427A1 (en) Polypeptide and pharmaceutical composition containing the polypeptide
WO2019231860A1 (en) Method for treating or preventing radiotherapy- and chemotherapy-associated oral mucositis using locally administered heparin binding epidermal growth factor like growth factor (hb-egf)
WO2025043075A1 (en) Methods of treating myocardial infarction, ischemia, and ischemia reperfusion injury
HK40047629B (zh) 皮肤病治疗剂
AU2025271034A1 (en) Engineered hemichannels, engineered vesicles, and uses thereof
TW202228766A (zh) 一種治療神經損傷及其相關病症的方法
HK40084760A (en) Method for treatment of nerve injury and related disease
HK40047629A (zh) 皮肤病治疗剂
HK1223294B (en) Therapeutic applications of smad7
HK1223294A1 (zh) Smad7的治疗应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191101

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191226